Answers are grounded in this paper and cite their sources.
The Surveillance, Epidemiology, and End Results (SEER) cancer registry contributed to technology assessment by providing population-based samples for detailed case-control studies, by serving as the control group in comparisons with various experimental groups, by allowing an assessment of selection bias in clinical trials, and by facilitating evaluations of classification and coding systems.
No takes yet. Share an insight, caveat, or question.
Klawansky et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: